Moderate to Severe Atopic Dermatitis Clinical Trials

58 clinical trials for Moderate to Severe Atopic Dermatitis across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis — RECRUITING · PHASE2
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis — RECRUITING · PHASE1
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — RECRUITING · PHASE3
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis — RECRUITING · PHASE3
Cross-sectional study on current care situation and treatment satisfaction of patients with atopic dermatitis (AD-Screen) — RECRUITING
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — RECRUITING · PHASE3
B7451031 - A Phase 3, Multicenter, Long-Term, Open-Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis — RECRUITING · PHASE3
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — RECRUITING · PHASE1
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis — RECRUITING · PHASE2
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. — RECRUITING · PHASE3
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis — RECRUITING · PHASE2
TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis — RECRUITING
Comparative, multicentre, randomised, double-blind study to assess the efficacy of tacrolimus 0.03% ointment versus fluticasone 0.005% ointment in children aged 2 years or over suffering from moderate to severe atopic dermatitis — COMPLETED · PHASE4
The aim of the study is to determine how safe and effective PF-04965842 is when taken as the treatment for moderate to severe atopic dermatitis in patients aged 12 years or older. — COMPLETED · PHASE3
A Phase II, Multicenter, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis — TERMINATED · PHASE2
A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis — TERMINATED · PHASE2
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis — ACTIVE_NOT_RECRUITING · PHASE2
B7451023 - A 16-Week, Multicenter, Interventional, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate Efficacy and Safety of Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — TERMINATED · PHASE3
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) — COMPLETED · PHASE3
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis — TERMINATED · PHASE2
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis — COMPLETED · PHASE2
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis — ACTIVE_NOT_RECRUITING · PHASE2
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial — COMPLETED · PHASE4
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis — TERMINATED · PHASE2
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis — COMPLETED
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis — COMPLETED · PHASE2
A Phase IV, non-randomized, open-label multinational trial to assess the mechanism of action for Lebrikizumab in moderate-to-severe atopic dermatitis — NOT_YET_RECRUITING · PHASE4
A phase 3, randomised, 2-arm, parallel-group, double-blind, placebo-controlled trial to evaluate the efficacy and safety of subcutaneous methotrexate versus placebo in moderate to severe atopic dermatitis — TERMINATED · PHASE3
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis — NOT_YET_RECRUITING · PHASE2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis — NOT_YET_RECRUITING · PHASE2
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis — COMPLETED · PHASE2
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis — NOT_YET_RECRUITING · PHASE3
A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis — NOT_YET_RECRUITING · PHASE2
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis — OTHER · PHASE2
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) — TERMINATED · PHASE1
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis — ACTIVE_NOT_RECRUITING · PHASE3
B7451015 - A PHASE 3 MULTICENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS — OTHER · PHASE3
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof of Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis — OTHER · PHASE2
The Study of CM310 in Patients With Atopic Dermatitis — COMPLETED · PHASE2
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis — ACTIVE_NOT_RECRUITING · PHASE3
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis — COMPLETED · PHASE3
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis — COMPLETED · PHASE3
Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis — COMPLETED · PHASE2
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China — COMPLETED · PHASE2
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable — WITHDRAWN · PHASE3
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — COMPLETED
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis — COMPLETED · PHASE2
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis — OTHER · PHASE2
The Study of CM326 in Moderate-to-severe Atopic Dermatitis — OTHER · PHASE2
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis — COMPLETED · PHASE2

Refine this search